ENOV on NYSE

Colfax Corporation

American medical technology company

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1995Founded1

Compare with MSA Safety, Align Technology or Bone Biologics Corp, or pick any stock.

  • TickerENOV on NYSE1
  • Industrymedical technology1
  • HeadquartersAnnapolis Junction1
  • Websitewww.colfaxcorp.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address2900 Lake Vista Drive, Suite 200, Lewisville, Tx 750674
  • Filer categoryLarge accelerated filer4

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV. The company has over 8,000 employees operating at 30 sites around the world.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.8%Gross margin6
-50.0%Operating margin6
-52.7%Net margin6
6.7%Revenue growth, 20256
-79.5%Return on equity6
0.85×Debt to equity6
$19.9MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Prevention and Recovery brought in 51% of the revenue Colfax Corporation broke down this way in fiscal 2025.

  1. Prevention and Recovery$1.1B651%up 4% from 2024
  2. Reconstructive$1.1B649%up 10% from 2024
Business segments by year
Business segments202320242025
Prevention and Recovery$1.1B$1.1B$1.1B
Reconstructive$630.4M$1.0B$1.1B

Regions

United States brought in 58% of the revenue Colfax Corporation broke down this way in fiscal 2025.

  1. United States$1.3B658%up 4% from 2024
  2. Foreign$952.7M642%up 11% from 2024
Regions by year
Regions202320242025
United States$1.2B$1.2B$1.3B
Foreign$554.8M$861.9M$952.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue40¢$902.8M
  • Research and development5¢$120.3M
  • Selling, general and admin48¢$1.1B
  • Other costs4¢$97.7M
  • Interest2¢$34.8M
  • Income tax1¢$22.3M

Out of $2.2B in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending91¢$197.4M
  • Share buybacks2¢$3.5M
  • Kept or used elsewhere8¢$16.4M

Out of $217.3M of cash from operations.6

Financial statements

Revenue789106$2.2B in 2025−32% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $3.3B$3.3B20192020: $1.1B$1.1B2020−66%2021: $1.4B$1.4B2021+27%2022: $1.6B$1.6B2022+10%2023: $1.7B$1.7B2023+9%2024: $2.1B$2.1B2024+23%2025: $2.2B$2.2B2025+7%
Gross profit789106$1.3B in 2025−4% since 2019
0$500.0M$1.0B$1.5B2019: $1.4B$1.4B20192020: $603.6M$603.6M2020−57%2021: $777.7M$777.7M2021+29%2022: $869.4M$869.4M2022+12%2023: $990.8M$990.8M2023+14%2024: $1.2B$1.2B2024+19%2025: $1.3B$1.3B2025+14%
Operating income789106-$1.1B in 2025
-$1.5B-$1.0B-$500.0M0$500.0M2019: $203.6M$203.6M20192020: -$66.2M-$66.2M20202021: -$62.8M-$62.8M2021−5%2022: -$71.2M-$71.2M2022+13%2023: -$65.7M-$65.7M2023−8%2024: -$775.7M-$775.7M2024+1081%2025: -$1.1B-$1.1B2025+45%
Net income789106-$1.2B in 2025+124% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$527.6M-$527.6M20192020: $42.6M$42.6M20202021: $71.7M$71.7M2021+68%2022: -$13.3M-$13.3M20222023: -$33.3M-$33.3M2023+150%2024: -$825.5M-$825.5M2024+2382%2025: -$1.2B-$1.2B2025+43%

Every line of the income statement in the latest annual report, as filed.6

Period ending2025-12-312024-12-312023-12-31
Net sales$2.2B$2.1B$1.7B
Cost of sales$902.8M$926.9M$716.4M
Gross profit$1.3B$1.2B$990.8M
Selling, general and administrative expense$1.1B$1.0B$830.3M
Research and development expense$120.3M$91.3M$75.3M
Amortization of acquired intangibles$173.6M$165.5M$133.5M
Purchase of royalty interest$45.8M$0$0
Restructuring and other charges$9.8M$27.3M$17.3M
Goodwill impairment$1.0B$645.0M$0
Operating loss-$1.1B-$775.7M-$65.7M
Interest expense, net$34.8M$57.1M$19.7M
Debt extinguishment charges$0$0$7.3M
Other (income) expense, net$367.0K-$9.9M-$25.7M
Loss from continuing operations before income taxes-$1.2B-$822.9M-$67.1M
Income tax expense (benefit)$22.3M$4.5M-$13.3M
Net loss from continuing operations-$1.2B-$827.4M-$53.8M
Income (loss) from discontinued operations, net of taxes-$1.9M$2.6M$21.1M
Net loss-$1.2B-$824.8M-$32.7M
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes$820.0K$679.0K$530.0K
Net loss attributable to Enovis Corporation-$1.2B-$825.5M-$33.3M
Continuing operations - basic (in usd per share)-$21-$15-$1
Discontinued operations - basic-$0$0$0
Consolidated operations - basic-$20.75-$14.93-$0.61
Continuing operations - diluted (in usd per share)-$21-$15-$1
Discontinued operations - diluted-$0$0$0
Consolidated operations - diluted-$20.75-$14.93-$0.61

Compare Colfax Corporation with another company

The story

Founded by Mitchell Rales in 1995.1

The company was founded in 1995 as the Colfax Corporation in Richmond, Virginia, by brothers Steven and Mitchell Rales. In August 1997, Colfax acquired approximately 93% of IMO's common stock through a public tender offer. At the time of the acquisition, IMO was a diversified industrial manufacturer, with $469.0 million in annual revenue and five business units: Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Simultaneously with the closing of the tender offer, IMO divested its Gems Sensors and Roltra Morse units to narrow the strategic focus to power transmission and fluid handling.

In January 2012, Colfax completed the acquisition of Charter International, successor to the British South Africa Company, and the parent company of ESAB (welding and cutting) and Howden (air and gas handling products), for $2.4 billion. More than 25 acquisitions were completed from 2012–2019 to build-out the three industrial businesses, fluid handling, fabrication technologies (ESAB), and air & gas handling (Howden).

In December 2017, Colfax sold its original fluid handling platform to Circor International for cash and stock with a total estimated aggregate consideration of $860 million. In November 2018, Colfax expanded into the medical device space by acquiring DJO Global from The Blackstone Group for $3.15bn. In May 2019, KPS Capital Partners (KPS) announced that it has signed an agreement to acquire Howden Turbo from Colfax Corporation for $1.8bn.

In March 2021, Colfax announced that it would spin off its ESAB industrial business in a tax-efficient manner and pursue a focused medical technologies strategy. This spin-off was completed in April 2022, following which ESAB became an independent public company and Colfax was renamed Enovis. The spin-off was the final action taken to transform the portfolio of businesses from purely industrial to medical technologies. These actions included divesting the fluid handling and air and gas handling businesses in 2017 and 2019, respectively, and acquiring DJO Global in 2019. Additional acquisitions were made, and Colfax went public with an initial public offering in May 2008 as a fluid handling company. The headquarters were subsequently moved to Annapolis Junction, Maryland.

In September 2023, Enovis announced that it had reached a definitive agreement to acquire the Villanova di San Daniele del Friuli-headquartered medical device company LimaCorporate for approximately €800 million. On January 3, 2024, it was reported that the purchase of LimaCorporate had been completed.

From Wikipedia’s article on Enovis, shared under CC BY-SA 4.0.5

Leadership

Who has led Colfax Corporation, and when. Pick a name to see everywhere that person has worked.

Subsidiaries and ownership

Subsidiaries

  • Howden ČKD Compressors

From Wikidata.1

Acquisitions

  1. 2015Acquired Roots Blowers1

Former names

  • Colfax CORPJan 4, 2008 to Mar 18, 20224

Timeline

  1. 1995Founded Founded1

Recent filings

  1. Oct 1, 20264
  2. Sep 8, 20264
  3. Sep 4, 20264
  4. Sep 4, 20264
  5. Sep 1, 20268-K
  6. Aug 14, 2026SCHEDULE 13G
  7. Aug 6, 20268-K
  8. Aug 6, 202610-Q
  9. Jul 28, 2026SCHEDULE 13G/A
  10. Jul 8, 2026SCHEDULE 13G/A
  11. Jul 1, 20264
  12. Jun 26, 202611-K
  13. Jun 16, 20264/A
  14. Jun 16, 20264
  15. Jun 15, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2